nach oben

Journal of Neurology

Erschienen in:

01.07.2012 | Medical Progress in the Journal of Neurology

Progress in multiple sclerosis research in the last year

verfasst von: Daniela Galimberti, Elio Scarpini

Erschienen in: Journal of Neurology | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Herein, we summarize the main articles describing novel findings in multiple sclerosis published in the Journal of Neurology over the last year, including clinical, therapeutic and research issues.

Chaudhuri A, Behan PO (2004) Fatigue in neurological disorders. Lancet 363:978–988PubMedCrossRef

Yaldizli Ö, Glassl S, Sturm D, Papadopoulou A, Gass A, Tettenborn B, Putzki N (2011) Fatigue and progression of corpus callosum atrophy in multiple sclerosis. J Neurol 258:2199–2205PubMedCrossRef

Morgante F, Dattola V, Crupi D, Russo M, Rizzo V, Ghilardi MF et al (2012) Is central fatigue in multiple sclerosis a disorder of movement preparation? J Neurol 258:263–272CrossRef

Horowski S, Zettl UK, Benecke R, Walter U (2012) Sonographic basal ganglia alterations are related to non-motor symptoms in multiple sclerosis. J Neurol 258:195–202CrossRef

Judica E, Martinelli Boneschi F, Ungaro D, Comola M, Gatti R, Comi G, Rossi P (2012) Impact of fatigue on the efficacy of rehabilitation in multiple sclerosis. J Neurol 258:835–839CrossRef

Sacco R, Bussman R, Oesch P, Kesselring J, Beer S (2012) Assessment of gait parameters and fatigue in MS patients during inpatient rehabilitation: a pilot trial. J Neurol 258:889–894CrossRef

Mori F, Ljoka C, Magni E, Codecà C, Kusayanagi H, Monteleone F et al (2011) Transcranial magnetic stimulation primes the effect of exercise therapy in multiple sclerosis. J Neurol 258:1281–1287PubMedCrossRef

McNicholas N, Chataway J (2011) Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination. J Neurol 258:1545–1547PubMedCrossRef

Wipfler P, Pilz G, Broussalis E, Golaszewski SM, Kunz A, Trinka E, Kraus J (2011) Acute pulmonary edema caused by a multiple sclerosis relapse. J Neurol 258:1176–1179PubMedCrossRef

10.

Valentino P, Nisticò R, Pirritano D, Bilotti G, Del Giudice F, Sturniolo M, Quattrone A (2011) Lamotrigine therapy for paroxysmal dysarthria caused by multiple sclerosis: a case report. J Neurol 258:1349–1350PubMedCrossRef

11.

Nociti V, Batocchi AP, Luigetti M, Conte A, Lorusso VS, Roiati S et al (2011) Progressive ascending myelopathy: atypical forms of multiple sclerosis or what else? J Neurol 258:1965–1970PubMedCrossRef

12.

Häne A, Bargetzi M, Hewer E, Bruehlmeier M, Khamis A, Roelcke U (2011) Recurrent tumefactive demyelination without evidence of multiple sclerosis or brain tumor. J Neurol 258:318–320PubMedCrossRef

13.

Morrow SA, Jurgensen S, Forrestal F, Munchauer FE, Benedict RHB (2012) Effects of acute relapses on neuropsychological status in multiple sclerosis patients. J Neurol 258:1603–1608CrossRef

14.

Nocentini U, Pasqualetti P, Bonavita S, Buccafusca M, De Caro MF, Farina D et al (2006) Cognitive dysfunctions in patients with relapsing-remitting multiple sclerosis. Mult Scler 12:77–87PubMedCrossRef

15.

Akbar N, Honarmand K, Kou N, Feinstein A (2011) Validity of a computerized version of the Symbol Digit Modalities Test in multiple sclerosis. J Neurol 258:373–379PubMedCrossRef

16.

Honarmand K, Akbar N, Kou N, Feinstein A (2011) Predicting employment status in multiple sclerosis patients: the utility of the MS functional composite. J Neurol 258:244–249PubMedCrossRef

17.

Zaaraoui W, Reuter F, Rico A, Faivre A, Crespy L, Malikova I et al (2011) Occurrence of neuronal dysfunction during the first 5 years of multiple sclerosis is associated with cognitive deterioration. J Neurol 258:811–819PubMedCrossRef

18.

Reis A, Mateus C, Macário MC, Faria de Abreu JR, Castelo-Branco M (2011) Independent patterns of damage to retinocortical pathways in multiple sclerosis without a previous episode of optic neuritis. J Neurol 258:1695–1704PubMedCrossRef

19.

Healy B, Chitnis T, Engler D (2011) Improving power to detect disease progression in multiple sclerosis through alternative analysis strategies. J Neurol 258:1812–1819PubMedCrossRef

20.

Invernizzi P, Bertolasi L, Bianchi MR, Turatti M, Gajofatto A, Benedetti MD (2011) Prognostic value of multimodal evoked potentials in multiple sclerosis: the EP score. J Neurol 258:1933–1939PubMedCrossRef

21.

Jozefowicz-Korczynska M, Pajor AM (2011) Evaluation of the smooth pursuit tests in multiple sclerosis patients. J Neurol 258:1795–1800PubMedCrossRef

22.

Prochnow D, Donell J, Schäfer R, Jörgens S, Hartung HP, Franz M, Seitz RJ (2011) Alexithymia and impaired facial affect recognition in multiple sclerosis. J Neurol 258:1683–1688PubMedCrossRef

23.

Argyriou AA, Iconomou G, Ifanti AA, Karanasios P, Assimakopoulos K, Makridou A et al (2011) Religiosity and its relation to quality of life in primary caregivers of patients with multiple sclerosis: a case study in Greece. J Neurol 258:1114–1119PubMedCrossRef

24.

Malucchi S, Gilli F, Caldano M, Sala A, Capobianco M, di Sapio A et al (2011) One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. J Neurol 258:895–903PubMedCrossRef

25.

Menge T, Hartung HP, Kieseier BC (2011) Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now. J Neurol 258:904–907PubMedCrossRef

26.

Zwibel H, Pardo G, Smith S, Denney D, Oleen-Burkey M (2011) A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. J Neurol 258:402–411PubMedCrossRef

27.

Hellwig K, Gold R (2011) Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis. J Neurol 258:502–503PubMedCrossRef

28.

Lebrun C, Vermersch P, Brassat D, Defer G, Rumbach L, Clavelou P et al (2011) Cancer and multiple sclerosis in the era of disease-modifying treatments. J Neurol 258:1304–1311PubMedCrossRef

29.

Havla J, Gerdes LA, Meinl I, Krumbholz M, Faber H, Weber F, Pellkofer HL et al (2011) De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol 258:1665–1669PubMedCrossRef

30.

Magraner MJ, Coret F, Navarré A, Boscá I, SimóM Escutia M et al (2011) Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study. J Neurol 258:1805–1811PubMedCrossRef

31.

MacManus DG, Miller DH, Kappos L, Gold R, Havrdova E, Limmroth V et al (2011) BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol 258:449–456PubMedCrossRef

32.

Duddy M, Haghikia A, Cocco E, Eggers C, Drulovic J, Carmona O et al (2011) Managing MS in a changing treatment landscape. J Neurol 258:728–739PubMedCrossRef

33.

Fjeldstad AS, McDaniel J, Witman MAH, Ives SJ, Zhao J, Rose JW et al (2011) Vascular function and multiple sclerosis. J Neurol 258:2036–2042PubMedCrossRef

34.

Steffensen LH, Jørgensen L, Straume B, Ivar Mellgren S, Kampman MT (2011) Can vitamin D₃ supplementation prevent bone loss in persons with MS? A placebo-controlled trial. J Neurol 258:1624–1631PubMedCrossRef

35.

Munger KL, Chitnis T, Frazier AL, Giovannucci E, Spiegelman D, Ascherio A (2011) Dietary intake of vitamin D during adolescence and risk of multiple sclerosis. J Neurol 258:479–485PubMedCrossRef

36.

Simon KC, Munger KL, Kraft P, Hunter DJ, De Jager PL, Ascherio A (2011) Genetic predictors of 25-hydroxyvitamin D levels and risk of multiple sclerosis. J Neurol 258:1676–1682PubMedCrossRef

37.

Koutsis G, Karadima G, Floroskufi P, Sfagos C, Vassilopoulos D, Panas M (2011) The rs10492972 KIF1B polymorphism and disease progression in Greek patients with multiple sclerosis. J Neurol 258:1726–1728PubMedCrossRef

38.

Aulchenko YS, Hoppenbrouwers IA, Ramagopalan SV, Broer L, Jafari N, Hillert J et al (2008) Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat Genet 40:1402–1403PubMedCrossRef

39.

Edwards LJ, Sharrack B, Ismail A, Tumani H, Constantinesku CS (2011) Central inflammation versus peripheral regulation in multiple sclerosis. J Neurol 258:1518–1527PubMedCrossRef

40.

Axelsson M, Malmeström C, Nilsson S, Haghighi S, Rosengren L, Lycke J (2011) Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. J Neurol 258:882–888PubMedCrossRef

Titel: Progress in multiple sclerosis research in the last year
verfasst von: Daniela Galimberti
Elio Scarpini
Publikationsdatum: 01.07.2012
Verlag: Springer-Verlag
Erschienen in: Journal of Neurology / Ausgabe 7/2012
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-012-6578-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2012

Evolution of MS lesions to black holes under DNA vaccine treatment

Trigger factors for rupture of intracranial aneurysms in relation to patient and aneurysm characteristics

Nerve conduction and electromyography studies

The more things change the more they stay the same: a case report of neurology residency experiences

Obstructive sleep apnea linked to wake-up strokes